Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk fartors, angiographic coronary artery disease, and major adverse events at follow-up

Emmanouil S. Brilakis, Joseph P. McConnell, Ryan J. Lennon, Ahmad A. Elesber, Jeffrey G. Meyer, Peter B. Berger

Research output: Contribution to journalArticle

193 Citations (Scopus)

Abstract

Aims: We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary artery disease (CAD) risk factors, with the severity of angiographic CAD, and with the incidence of major adverse events. Methods and results: We measured Lp-PLA2 levels in 504 consecutive patients undergoing clinically indicated coronary angiography. Mean age was 60 ± 11 years and 38% were women. The mean (± SD) Lp-PLA2 level (ng/mL) was 245 ± 91. Lp-PLA2 levels correlated with male gender, LDL, HDL, and total cholesterol, fibrinogen, and creatinine. Lp-PLA2 levels correlated with the extent of angiographic CAD on univariate but not on multivariable analysis. During a median follow-up of 4.0 years, 72 major adverse events occurred in 61 of 466 (13%) contacted patients (20 deaths, 14 myocardial infarctions, 28 coronary revascularizations, and 10 strokes). Higher Lp-PLA2 levels were associated with a greater risk of events: the hazard ratio per SD was 1.28 (95% CI 1.06-1.54, P = 0.009), and remained significant after adjusting for clinical and lipid variables and C-reactive protein. Conclusion: Higher Lp-PLA2 levels were associated with a higher incidence of major adverse events at follow-up, independently of traditional CAD risk factors and C-reactive protein.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalEuropean Heart Journal
Volume26
Issue number2
DOIs
StatePublished - Jan 2005

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Coronary Artery Disease
C-Reactive Protein
Incidence
Coronary Angiography
Fibrinogen
HDL Cholesterol
Creatinine
Stroke
Myocardial Infarction
Lipids

Keywords

  • Acute myocardial infarction
  • C-reactive protein
  • Coronary disease
  • Lipoprotein-associated phospholipase A2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk fartors, angiographic coronary artery disease, and major adverse events at follow-up. / Brilakis, Emmanouil S.; McConnell, Joseph P.; Lennon, Ryan J.; Elesber, Ahmad A.; Meyer, Jeffrey G.; Berger, Peter B.

In: European Heart Journal, Vol. 26, No. 2, 01.2005, p. 137-144.

Research output: Contribution to journalArticle

@article{89d37549263d49df9a4152ea5e9d5997,
title = "Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk fartors, angiographic coronary artery disease, and major adverse events at follow-up",
abstract = "Aims: We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary artery disease (CAD) risk factors, with the severity of angiographic CAD, and with the incidence of major adverse events. Methods and results: We measured Lp-PLA2 levels in 504 consecutive patients undergoing clinically indicated coronary angiography. Mean age was 60 ± 11 years and 38{\%} were women. The mean (± SD) Lp-PLA2 level (ng/mL) was 245 ± 91. Lp-PLA2 levels correlated with male gender, LDL, HDL, and total cholesterol, fibrinogen, and creatinine. Lp-PLA2 levels correlated with the extent of angiographic CAD on univariate but not on multivariable analysis. During a median follow-up of 4.0 years, 72 major adverse events occurred in 61 of 466 (13{\%}) contacted patients (20 deaths, 14 myocardial infarctions, 28 coronary revascularizations, and 10 strokes). Higher Lp-PLA2 levels were associated with a greater risk of events: the hazard ratio per SD was 1.28 (95{\%} CI 1.06-1.54, P = 0.009), and remained significant after adjusting for clinical and lipid variables and C-reactive protein. Conclusion: Higher Lp-PLA2 levels were associated with a higher incidence of major adverse events at follow-up, independently of traditional CAD risk factors and C-reactive protein.",
keywords = "Acute myocardial infarction, C-reactive protein, Coronary disease, Lipoprotein-associated phospholipase A2",
author = "Brilakis, {Emmanouil S.} and McConnell, {Joseph P.} and Lennon, {Ryan J.} and Elesber, {Ahmad A.} and Meyer, {Jeffrey G.} and Berger, {Peter B.}",
year = "2005",
month = "1",
doi = "10.1093/eurheartj/ehi010",
language = "English (US)",
volume = "26",
pages = "137--144",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk fartors, angiographic coronary artery disease, and major adverse events at follow-up

AU - Brilakis, Emmanouil S.

AU - McConnell, Joseph P.

AU - Lennon, Ryan J.

AU - Elesber, Ahmad A.

AU - Meyer, Jeffrey G.

AU - Berger, Peter B.

PY - 2005/1

Y1 - 2005/1

N2 - Aims: We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary artery disease (CAD) risk factors, with the severity of angiographic CAD, and with the incidence of major adverse events. Methods and results: We measured Lp-PLA2 levels in 504 consecutive patients undergoing clinically indicated coronary angiography. Mean age was 60 ± 11 years and 38% were women. The mean (± SD) Lp-PLA2 level (ng/mL) was 245 ± 91. Lp-PLA2 levels correlated with male gender, LDL, HDL, and total cholesterol, fibrinogen, and creatinine. Lp-PLA2 levels correlated with the extent of angiographic CAD on univariate but not on multivariable analysis. During a median follow-up of 4.0 years, 72 major adverse events occurred in 61 of 466 (13%) contacted patients (20 deaths, 14 myocardial infarctions, 28 coronary revascularizations, and 10 strokes). Higher Lp-PLA2 levels were associated with a greater risk of events: the hazard ratio per SD was 1.28 (95% CI 1.06-1.54, P = 0.009), and remained significant after adjusting for clinical and lipid variables and C-reactive protein. Conclusion: Higher Lp-PLA2 levels were associated with a higher incidence of major adverse events at follow-up, independently of traditional CAD risk factors and C-reactive protein.

AB - Aims: We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary artery disease (CAD) risk factors, with the severity of angiographic CAD, and with the incidence of major adverse events. Methods and results: We measured Lp-PLA2 levels in 504 consecutive patients undergoing clinically indicated coronary angiography. Mean age was 60 ± 11 years and 38% were women. The mean (± SD) Lp-PLA2 level (ng/mL) was 245 ± 91. Lp-PLA2 levels correlated with male gender, LDL, HDL, and total cholesterol, fibrinogen, and creatinine. Lp-PLA2 levels correlated with the extent of angiographic CAD on univariate but not on multivariable analysis. During a median follow-up of 4.0 years, 72 major adverse events occurred in 61 of 466 (13%) contacted patients (20 deaths, 14 myocardial infarctions, 28 coronary revascularizations, and 10 strokes). Higher Lp-PLA2 levels were associated with a greater risk of events: the hazard ratio per SD was 1.28 (95% CI 1.06-1.54, P = 0.009), and remained significant after adjusting for clinical and lipid variables and C-reactive protein. Conclusion: Higher Lp-PLA2 levels were associated with a higher incidence of major adverse events at follow-up, independently of traditional CAD risk factors and C-reactive protein.

KW - Acute myocardial infarction

KW - C-reactive protein

KW - Coronary disease

KW - Lipoprotein-associated phospholipase A2

UR - http://www.scopus.com/inward/record.url?scp=14144256273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14144256273&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehi010

DO - 10.1093/eurheartj/ehi010

M3 - Article

VL - 26

SP - 137

EP - 144

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 2

ER -